Welcome to our dedicated page for Tenet Healthcare SEC filings (Ticker: THC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Tenet Healthcare’s disclosures can feel like triaging a busy emergency room—hundreds of pages, three operating segments, and intricate Medicare rules pack every document. Whether you need Tenet Healthcare insider trading Form 4 transactions or the cash-flow detail buried in the Tenet Healthcare quarterly earnings report 10-Q filing, raw EDGAR text alone slows decisions.
Stock Titan’s AI quickly converts that overload into plain language. Our engine delivers Tenet Healthcare SEC filings explained simply, highlighting hospital occupancy swings, ambulatory surgery center margins, and Conifer Health Solutions revenue trends. Get push alerts for Tenet Healthcare Form 4 insider transactions real-time, one-click access to management’s risk commentary, and contextual charts that transform numbers into insight.
Use cases investors rely on:
- Compare segment EBITDAR across periods with Tenet Healthcare earnings report filing analysis.
- Answer board questions by understanding Tenet Healthcare SEC documents with AI instead of skimming 300 pages.
- Monitor sentiment via Tenet Healthcare executive stock transactions Form 4 before earnings calls.
The platform covers every form in real time. The Tenet Healthcare annual report 10-K simplified section surfaces payer-mix tables and litigation reserves; the Tenet Healthcare proxy statement executive compensation view breaks down incentive targets; and Tenet Healthcare 8-K material events explained flags sudden divestitures or ASC acquisitions within minutes. From first-read AI summaries to full PDF text, every filing is one search away—so you can focus on diagnosing value, not decoding jargon.
Tenet Healthcare (THC) reported Q3 2025 results. Net operating revenues were $5,289 million versus $5,126 million a year ago. Operating income was $889 million. Net income available to common shareholders was $342 million, with diluted EPS of $3.86.
Ambulatory Care continued to expand, generating $1,275 million in net operating revenues in the quarter, up from $1,139 million. For the first nine months, operating cash flow reached $2,809 million, supporting capital spending and equity returns. The company repurchased 7,828 thousand shares year‑to‑date at an average price of $151.75, and the board increased the 2024 share repurchase program in July; $1,688 million remained authorized at September 30.
Cash and cash equivalents were $2,975 million, and long‑term debt (net of current portion) was $13,102 million. As of October 22, 2025, shares outstanding were 87,885 thousand. Tenet highlighted a new FASB practical expedient (ASU 2025‑05) it is evaluating and noted U.S. tax law changes enacted in July 2025 that reduce taxable income through bonus depreciation and interest deduction adjustments.
Tenet Healthcare Corporation furnished a Form 8-K under Item 2.02 to announce it issued a press release with financial results for the quarter ended September 30, 2025. The company attached the release as Exhibit 99.1 and incorporated it by reference.
The information was furnished, not filed, under the Exchange Act. Tenet lists its securities as common stock (THC) and 6.875% Senior Notes due 2031 (THC31).
Saumya Sutaria, identified as both a director and the CEO of Tenet Healthcare Corp (THC), reported the sale of common stock on 09/10/2025. The Form 4 discloses two separate sale transactions: 59,456 shares sold at a weighted average price of $190.48 (prices ranged $190.14–$191.05) and 19,306 shares sold at a weighted average price of $191.70 (prices ranged $191.18–$192.06), for a total of 78,762 shares sold. Following the reported transactions, beneficial ownership is reported as 387,989 shares after the first set of sales and 368,683 shares after the second set. The Form 4 is dated and signed on behalf of Ms. Sutaria by an attorney-in-fact, Chad J. Wiener, on 09/12/2025. The filing includes undertakings to provide breakouts of shares sold at each price upon request.
Form 144 notice for proposed sale of securities. The filing reports an intended sale of 78,762 shares of Common stock through Fidelity Brokerage Services LLC on or about 09/10/2025 with an aggregate market value of $15,025,892.48. The shares were acquired on 08/31/2025 via restricted stock vesting from the issuer and the payment type is listed as compensation. The filing states there were no securities sold in the past three months. Several issuer identification fields (including the issuer name and SEC file number) are not populated in the provided content.
Saumya Sutaria, CEO and director of Tenet Healthcare Corporation (THC), reported vesting and related transactions on 08/29/2025. A grant of 53,341 time-based restricted stock units from 2021 vested in full and converted one-for-one into 53,341 shares. Following the vesting and subsequent share transfers to cover taxes and other dispositions, the filing shows Sutaria beneficially owned 447,445 shares.
The filing records shares withheld for taxes: 27,087 shares withheld upon vesting and 54,174 shares delivered to satisfy withholding for performance share units. The report states a reported disposition of 53,341 shares under transaction code M for the conversion event and lists a closing stock price of $184.33 used in the withholding calculation.
Insider sale disclosed: Tenet Healthcare director Christopher S. Lynch reported a sale of 12,350 shares of Tenet Healthcare Corp (ticker: THC) on 08/28/2025 at a reported price of $183.44 per share. The Form 4 was signed by Chad J. Wiener as attorney-in-fact on 08/29/2025. The sale is reported as a direct disposition by the reporting person.
Lisa Y. Foo, Executive Vice President and Chief Operating Officer of Tenet Healthcare Corporation (THC), reported the sale of 8,000 shares of Tenet common stock on 08/20/2025 at a weighted average price of $179.53 per share. After the reported disposition, the reporting person beneficially owned 20,878 shares, held directly. The Form 4 was signed by an attorney-in-fact, Chad J. Wiener, on 08/22/2025. The filer indicates the aggregate sale included multiple transactions with prices ranging from $179.22 to $179.74, and offers to provide detailed per-transaction quantities on request.
Tenet Healthcare insider sale: Director Christopher S. Lynch sold 3,952 shares of Tenet Healthcare Corporation common stock on 08/19/2025 at a reported price of $176.39 per share, leaving him with 12,358 shares beneficially owned after the sale. The Form 4 was signed by an attorney-in-fact on 08/21/2025. The filing identifies Lynch as a director and the transaction is a direct sale of common stock.
Tenet Healthcare (THC) Form 144 summary: An insider filed a notice to sell 8,000 common shares through Fidelity Brokerage Services on or about 08/20/2025. The filing lists an aggregate market value of $1,436,278.72 and total shares outstanding of 88,351,000, meaning the proposed sale equals approximately 0.0091% of outstanding shares. All 8,000 shares were acquired by restricted stock vesting from the issuer as compensation on dates in 2023 and 2024 (658; 1,088; 3,946; 2,308). The filer reports no securities sold in the past three months and makes the required representation about lack of undisclosed material information.
Tenet Healthcare exec Sun Park had 20,707 restricted stock units (RSUs) convert into common stock on 08/13/2025 after a relocation-based vesting condition was met. The RSUs convert one-for-one into common shares, bringing Park's post-transaction direct beneficial ownership to 23,392 shares. To cover taxes on vesting, 8,813 shares were withheld at an effective value of $171.87 per share, leaving 14,579 shares retained. The RSUs were originally granted on July 17, 2023 under the 2019 Stock Incentive Plan and exercised via standard vesting mechanics.
FAQ
What is the current stock price of Tenet Healthcare (THC)?
What is the market cap of Tenet Healthcare (THC)?
